Impactiviti Daily 012110

TODAY’S NEWS

Note: if you’re going to engage in questionable marketing practices, documenting it in Powerpoint is probably not a “best practice”! Just saying…

Experiment HIV drug from Merck fails in late-stage studies – Merck & Co  on Wednesday said its experimental HIV treatment vicriviroc proved ineffective in two late-stage studies involving patients who had previously been treated with other HIV medicines...more

Merck diarrhea drug does very well – Merck & Co.’s experimental drug against a germ blamed for increasing rates of deadly diarrhea in U.S. hospitals and nursing homes cut repeat infections by 72 percent, a study in the New England Journal of Medicine said…more

Orphan drug applications are way up.

Upcoming oral MS drugs are very promising – Study results suggest they are much more effective than expensive “disease modifying” MS drugs such as beta interferon and glatiramer acetate, which have to be injected….more

Top biotech layoffs of 2009.

RECOMMENDED

Curriculum Analysis – We have partners that can analyze your current curriculum to insure it is tightly connected to key strategies and goals, identify gaps and build learning paths that support measurable results for key roles in your organization. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

E-detailing – Pfizer doubles its spending. I expect this trend to accelerate across the industry. It simply makes sense.

JUST FOR FUN